Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 970 / https://doi.org/10.3332/ecancer.2019.970

Case Report

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)1 exposure. Data regarding the efficacy and safety of osimertinib rechallenge, especially in the setting of central nervous system (CNS) metastases, are scarce. We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. This dose reduction strategy may be an option for selected patients with brain metastases after tyrosine kinase inhibitors-induced AEs.

Keywords: lung cancer, osimertinib, immunotherapy, pneumonitis, rechallenge, brain metastases

Loading Article Metrics ... Please wait

Related articles

Research: Histopathologic patterns of cutaneous malignancies in individuals with oculocutaneous albinism in Anambra state, Nigeria: a paradigm swing?

Abstract | Full Article | PDF Published: 20 Feb 2020 / https://doi.org/10.3332/ecancer.2020.1013

Case Report: Multiple myeloma with concurrent immune thrombocytopenic purpura

Abstract | Full Article | PDF Published: 20 Feb 2020 / https://doi.org/10.3332/ecancer.2020.1012

Case Report: The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases

Abstract | Full Article | PDF Published: 17 Feb 2020 / https://doi.org/10.3332/ecancer.2020.1011

Case Report: Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin

Abstract | Full Article | PDF Published: 13 Feb 2020 / https://doi.org/10.3332/ecancer.2020.1010

Case Report: Multiple malignant transformations of an ovarian mature cystic teratoma

Abstract | Full Article | PDF Published: 04 Feb 2020 / https://doi.org/10.3332/ecancer.2020.1009



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation